Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Amphotericin B Liposome for Injection
NCT06977490Completed
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- May 2025
- Primary completion
- Oct 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of liposomal amphotericin b in invasive fungal infection (IFI), neutropenic fever and visceral leishmaniasis (VL) (2 arms), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to time t and 3 more. Started May 2025; status: completed.
02
Drugs
liposomal amphotericin b
03
Conditions
invasive fungal infection (IFI)neutropenic fevervisceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT06977490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977490.